A Phase II Study of LY2880070 and Gemcitabine in People with Ewing Sarcoma or Ewing-Like Sarcoma

Share
Print

Full Title

A Phase II Study of Oral CHK1 Inhibitor LY2880070 in Combination with Low-Dose Gemcitabine in Patients with Relapsed or Refractory Ewing Sarcoma

Purpose

Researchers are doing this study to find out if the investigational drug LY2880070 combined with the chemotherapy drug gemcitabine is safe and effective for treating people with Ewing sarcoma or Ewing-like sarcoma that has come back or continued to grow despite treatment.

LY2880070 blocks a protein called CHK1, which helps cancer cells repair damaged DNA. By blocking CHK1, LY2880070 may slow or stop the growth of cancer. LY2880070 is taken orally (by mouth) and gemcitabine is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have Ewing sarcoma or Ewing-like sarcoma that has come back or continued to grow despite no more than four prior regimens of treatment.
  • At least 3 weeks must pass since the completion of prior therapy (2 weeks since radiation therapy) and receipt of the study treatment.
  • Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
  • This study is for people of all ages, as long as they weigh at least 40 kg (88 pounds).

For more information about this study and to inquire about eligibility, please contact 1-833-MSK-KIDS

Protocol

21-428

Phase

II

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators

Diseases